Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304). Study has been terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- ACTIVE_NOT_RECRUITING
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 599
- sponsor
- Novartis Pharmaceuticals
- conditions
- Atherosclerotic Cardiovascular Disease
- interventions
- DRUG: Pelacarsen (TQJ230)
- start date
- 2025-05-19
- start date type
- ACTUAL
- primary completion date
- 2030-12-08
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT06875973
- Published
- Mar 14, 2025
- Updated
- Oct 14, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT06875973
- Categories
- Atherosclerotic Cardiovascular Disease
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials